PASSAGE BIO INC. DL-,0001 Aktie

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones. “We are pleased to share updated data highlighting the promise of PBFT02 for the frontotemporal dementia community.» Mehr auf globenewswire.com

Squarepoint Ops LLC grew its holdings in shares of Passage Bio, Inc. (NASDAQ:PASG – Free Report) by 129.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,099 shares of the company’s stock after acquiring an additional 36,172 shares during the quarter. Squarepoint Ops LLC owned 0.10% of Passage Bio worth $36,000 at the end of the most recent quarter. Other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in shares of Passage Bio by 983.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 54,479 shares of the company’s stock valued at $31,000 after buying an additional 49,449 shares during the period. Northern Trust Corp increased its stake in shares of Passage Bio by 55.1% in the fourth quarter. Northern Trust Corp now owns 62,476 shares of the company’s stock valued at $35,000 after buying an additional 22,195 shares during the period. Jane Street Group LLC increased its stake in shares of Passage Bio by 537.2% in the fourth quarter. Jane Street Group LLC now owns 78,190 shares of the company’s stock valued at $44,000 after buying an additional 65,919 shares during the period. Shay Capital LLC increased its stake in shares of Passage Bio by 144.2% in the fourth quarter. Shay Capital LLC now owns 225,261 shares of the company’s stock valued at $128,000 after buying an additional 133,005 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Passage Bio by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 531,565 shares of the company’s stock valued at $302,000 after buying an additional 22,049 shares during the period. Institutional investors and hedge funds own 53.48% of the company’s stock. Passage Bio Price Performance Shares of Passage Bio stock opened at $0.48 on Wednesday. Passage Bio, Inc. has a 1 year low of $0.26 and a 1 year high of $1.33. The firm has a market cap of $29.80 million, a PE ratio of -0.41 and a beta of 1.71. The stock has a fifty day moving average price of $0.36 and a 200-day moving average price of $0.51. Passage Bio (NASDAQ:PASG – Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). As a group, equities analysts anticipate that Passage Bio, Inc. will post -1.03 EPS for the current fiscal year. Insiders Place Their Bets In other news, major shareholder Orbimed Advisors Llc sold 77,090 shares of Passage Bio stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $0.33, for a total transaction of $25,439.70. Following the completion of the sale, the insider now owns 6,885,572 shares in the company, valued at approximately $2,272,238.76. This trade represents a 1.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 233,660 shares of company stock worth $77,723 in the last quarter. 5.00% of the stock is owned by company insiders. Analyst Upgrades and Downgrades Separately, Chardan Capital reduced their target price on Passage Bio from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. View Our Latest Analysis on PASG Passage Bio Company Profile (Free Report) Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. Read More Five stocks we like better than Passage Bio What is a Microcap Stock? Everything You Need to Know AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway 3 Stocks to Consider Buying in October Casey’s Surges on Strong Q4, More Gains Likely Ahead About the Markup Calculator Government Mandate Sends eVTOL Stocks Flying» Mehr auf defenseworld.net

Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting Cash runway into 1Q 2027 PHILADELPHIA, May 13, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. “We made steady progress in executing against our core operational objectives this quarter as we focus on the enrollment of FTD-GRN and FTD-C9orf72 patients in our ongoing global Phase 1/2 upliFT-D trial of PBFT02,” said Will Chou, M.D.» Mehr auf globenewswire.com